Who Needs a Bone Marrow (Hematopoietic Stem Cell) Transplant? (2026 Guide)

Hematopoietic stem cell transplant is a treatment considered for high-risk acute leukemia where chemotherapy alone carries a high risk of relapse, lymphoma that has relapsed or failed to respond to treatment, multiple myeloma, and some cases of myelodysplastic syndrome — when age, overall condition, and organ function support it.

Key Takeaways

• Candidate conditions: high-risk acute leukemia (cases where chemotherapy alone carries a high risk of relapse), lymphoma that has relapsed or failed to respond to standard treatment, multiple myeloma as part of its treatment course, and some cases of myelodysplastic syndrome.
• Eligibility is determined not just by the disease itself but together with age, overall physical condition, and heart, lung, liver, and kidney function. If there is an active infection or reduced organ function, timing may be delayed or a lower-intensity approach considered.
• For acute leukemia, allogeneic transplant (donor cells) is more common, while for multiple myeloma and relapsed lymphoma, autologous transplant (the patient's own cells) is the more frequent choice.
• For allogeneic transplant, donors are sought in this order: siblings, haploidentical donors (parent or child, half-match), unrelated donors, then cord blood — so options remain even without a fully matched sibling.
• Korea's 5-year relative survival rate for leukemia is 55.7% (National Cancer Registration Statistics 2019–2023, National Cancer Information Center). This is a nationwide statistic, not an individual hospital's outcome, and results vary considerably by subtype and risk group.

In which cases is transplant judged necessary?

• In acute leukemia, even after induction chemotherapy achieves remission (no detectable cancer cells), if the risk group is judged to be high, the approach often moves to allogeneic hematopoietic stem cell transplant rather than additional chemotherapy alone. This is because the high-dose conditioning chemotherapy reduces residual cancer cells, while donor immune cells can also attack any remaining cancer cells — combining both effects.
• Transplant is also considered during treatment for lymphoma that has relapsed or failed to respond to standard therapy, and for multiple myeloma. For multiple myeloma, autologous transplant using the patient's own cells is more common, while for acute leukemia, allogeneic transplant using donor cells is more frequent.
• Some cases of myelodysplastic syndrome may also be candidates, but whether it is actually applied depends on the subtype and risk group.

Are there restrictions based on age or health status?

• Eligibility for transplant is assessed not only by disease type but together with age, overall physical condition, and heart, lung, liver, and kidney function. Because high-dose conditioning chemotherapy places a major burden on the body, if there is an active infection or reduced organ function, it may be difficult to tolerate conditioning — so timing may be delayed or a lower-intensity regimen considered.
• Before treatment begins, heart function, lung function, liver and kidney function, and infection status (hepatitis B, hepatitis C, HIV, tuberculosis, cytomegalovirus) are checked. Because treatment for blood cancers significantly suppresses immunity, these tests are a core part of the treatment plan.

If no suitable donor is found, is transplant impossible?

• There are still options even without a fully matched sibling. For allogeneic transplant, donors are sought in the order of siblings, haploidentical donors (half-matched, such as a parent or child), unrelated donors, and cord blood. Haploidentical transplant is an approach using a half-matched tissue type when no fully matched donor is available.
• Korea performs a large volume of hematopoietic stem cell transplants and has accumulated extensive experience with haploidentical transplant, which helps reduce situations where treatment is blocked due to inability to find a donor. Which route is actually feasible depends on the type of disease, age, and urgency of treatment, so an individualized review based on the family's HLA (tissue compatibility) test results is necessary.

What is the sequence of the transplant process?

• Step 1: Staging tests are performed along with assessments of heart, lung, liver, and kidney function and infection screening. For allogeneic transplant, the donor's tissue compatibility testing and health checks proceed in parallel.
• Step 2: A central venous catheter is placed, and conditioning chemotherapy over about one week clears out the diseased bone marrow.
• Step 3: On the scheduled day, hematopoietic stem cells are infused intravenously. This is closer to a blood transfusion than surgery and takes only a few dozen minutes.
• Step 4: The 2–4 weeks until engraftment are spent in a sterile isolation room, with fever, mouth sores, and low blood counts managed through transfusions and antibiotics.
• Step 5: After engraftment is confirmed, the patient is discharged but does not return home immediately — outpatient follow-up continues. For allogeneic transplant, monitoring for graft-versus-host disease and infection often continues until around 100 days post-transplant. The total stay, including 3–6 weeks of hospitalization, is typically 6–8 weeks.

FAQ — Which is right for me, autologous or allogeneic transplant?

Autologous transplant uses the patient's own hematopoietic stem cells collected in advance. There is no rejection reaction, but there is a possibility that cancer cells may be mixed in with the collected cells. Allogeneic transplant uses donor cells and can offer the benefit of attacking remaining cancer cells, but requires management of graft-versus-host disease. Autologous transplant is more common for multiple myeloma and relapsed lymphoma, while allogeneic transplant is more common for high-risk acute leukemia. The final decision is made by the treating medical team based on disease type, age, and organ function, taken together.

FAQ — How much does transplant improve survival?

How much transplant improves survival varies greatly by subtype and risk group, so it cannot be expressed as a single number. For reference, Korea's overall 5-year relative survival rate for leukemia is 55.7% (National Cancer Registration Statistics 2019–2023, National Cancer Information Center), compared with 68.6% from the U.S. SEER database (2016–2022). However, simple comparison is difficult because the two countries differ in the proportion of acute versus chronic cases and in age at diagnosis. These figures are nationwide statistics combining acute and chronic cases and do not predict an individual's outcome. Whether transplant is needed for your specific risk group should be determined through consultation with your medical team.

Sources and Notes

• This article was written based on notes on blood cancer and hematopoietic stem cell transplant (National Cancer Information Center, NCCN Patient Guidelines, Medical Korea, National Cancer Registration Statistics 2019–2023, SEER 2016–2022).
• This content is provided for general medical information purposes only, and diagnosis, treatment methods, and outcomes may vary depending on individual condition. Accurate diagnosis and treatment must be determined through consultation with a medical professional.